Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis
The study was designed to test the hypothesis whether a standardized, time-and score-oriented treatment following a strict evidence based algorithm is equally effective to a standard treatment regimen for moderate to severe atopic dermatitis.
Study Type: Mono-centre study, patients are blinded, physicians are randomized to either treat study- or controll group
Eligible are patients age 2 years or older with SCORAD >= 20 Duration: 12 Months, study visits every 4 weeks.
Primary endpoint is Difference between Baseline SCORAD and mean SCORAD under treatment.
Secundary endpoints are quality of life, safety and economic burden in both treatment groups.
|Moderate to Severe Atopic Dermatitis||Drug: Pimecrolimus Drug: Tacrolimus Drug: Prednisolone Drug: Ciclosporin A Drug: Dermatop|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
|Official Title:||Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00148746
|Department of Dermatology, TU Dresden|
|Dresden, Germany, 01307|
|Study Director:||Jochen M Schmitt, MD, MPH||Dpt. of Dermatology, Medical Faculty, Technical University Dresden, Germany|